Clinical features and antimicrobial resistance of community-acquired pneumonia caused by Klebsiella pneumoniae in infants.
- Author:
Li-Yun HE
1
;
Ying-Jian WANG
;
Ji-Mei LI
Author Information
- Publication Type:Journal Article
- MeSH: Community-Acquired Infections; drug therapy; Drug Resistance, Bacterial; Female; Humans; Infant; Infant, Newborn; Klebsiella Infections; drug therapy; Klebsiella pneumoniae; drug effects; Male; Pneumonia, Bacterial; drug therapy
- From: Chinese Journal of Contemporary Pediatrics 2012;14(11):827-829
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical features and antimicrobial resistance of community-acquired pneumonia caused by Klebsiella pneumoniae in infants.
METHODSThe clinical data of 65 infants with community-acquired pneumonia caused by Klebsiella pneumoniae between 2007 and 2011 were retrospectively studied.
RESULTSOf the 65 infants, 37 cases (57%) were aged ≤3 months, 17 cases (26%) over 4 months, 7 cases (11%) over 7 months and 4 cases (6%) between 13 and 24 months. There were no significant differences in clinical manifestations and chest X-ray features between the infants with community-acquired pneumonia caused by Klebsiella pneumoniae and those with other bacterial pneumonia. Forty strains (62%) of ESBLs-producing Klebsiella pneumoniae were detected. Klebsiella pneumoniae was 100% sensitive to imipenem, meropenem and amikacin but resistant to penicillins and cephalosporins. The resistance rates of ESBLs-producing strains to penicillins, cephalosporins, amoxicillin/clavulanic acid, ampicillin/sulbactam, compound sulfamethoxazole, gentamycin, ciprofloxacin and aztreonam were significantly higher than for non-ESBLs-producing strains. ESBLs-producing strains also showed multiple-drug resistance.
CONCLUSIONSCommunity-acquired pneumonia caused by Klebsiella pneumoniae is common in infants aged ≤3 months. ESBLs-producing strains are prevalent in community-acquired pneumonia caused by Klebsiella pneumoniae and demonstrate both high rates of drug resistance and multiple-drug resistance.